EGF and cancer: In exploring the clinically targeted therapeutic value of the four angiogenic genes, we identified piperlongumine as an inhibitor of the EGF/EGFR axis through the Cancer Therapeutics Response Portal (CTRP) database (http://portals.broadinstitute.org/ctrp/).